SCHEDULE: Longitude Capital Boosts Veradermics Stake to 12.5%

Longitude Capital and its affiliates, including board member Patrick G. Enright, reported a 12.5% beneficial ownership in Veradermics, Incorporated following recent IPO purchases and preferred stock conversions.

Summary

• Longitude Capital entities and individuals (Patrick G. Enright, Juliet Tammenoms Bakker) collectively hold 4,653,873 shares of Veradermics, Incorporated Common Stock.
• This represents 12.5% of the total 37,339,464 shares outstanding as of February 5, 2026, which includes the full exercise of the underwriters' option to purchase 2,261,647 additional shares of Common Stock.
• The ownership includes shares acquired through the conversion of Series B and Series C Preferred Stock into Common Stock on a one-for-10.067 basis, effective February 5, 2026, upon the Issuer's initial public offering (IPO).
• Additional Common Stock was purchased in the IPO on February 5, 2026, with Longitude Venture Partners V, L.P. (LVPV) buying 192,647 shares for approximately $3.3 million and Longitude 103.8 East, L.P. (L103) buying 882,353 shares for approximately $15.0 million, both at $17.00 per share.
• The Reporting Persons hold these securities for general investment purposes and may adjust their holdings based on market conditions and other factors.
• Reporting Persons have entered into lock-up agreements, restricting them from selling or transferring Veradermics securities for 180 days following the underwriting agreement date for the Offering.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it indicates strong continued institutional support and significant investment from a venture capital firm and its principals, including a board member, following the company's IPO.

Positives

• Significant investment by venture capital firms and their principals, indicating confidence in Veradermics' long-term prospects.
• Patrick G. Enright, a managing member of the general partners of the investing entities, is also a member of Veradermics' board of directors, aligning investor and company interests.
• The participation in the IPO by existing investors suggests continued support for the company post-listing.

Risks

• Reporting Persons may increase or decrease their investment in the Issuer at any time, which could impact share price volatility.
• The 180-day lock-up agreement restricts sales by Reporting Persons, but the expiration of this period could lead to increased selling pressure.

Future Outlook

The Reporting Persons intend to continuously review their investment in Veradermics and may adjust their holdings by acquiring or disposing of shares based on market conditions, the Issuer's business prospects, and other investment opportunities. They have no present plans for other specific transactions beyond general investment purposes.

Management Comments

• Patrick G. Enright, a member of Veradermics' board of directors, and Juliet Tammenoms Bakker are managing members of the general partners of the investing entities, and may each be deemed to share voting and dispositive power over the reported shares.

Industry Context

StockSavvy.ai notes that significant venture capital backing, especially from firms like Longitude Capital, is common for emerging biotechnology or pharmaceutical companies like Veradermics, particularly around their initial public offering. The continued investment post-IPO by existing preferred shareholders, including a board member, signals a strong belief in the company's long-term potential within the competitive life sciences sector.

Comparison to Industry Standards

• StockSavvy.ai observes that a 12.5% beneficial ownership by a key institutional investor group, including a board member, is a substantial stake for a newly public company. This level of insider and institutional alignment is often viewed positively, similar to the early-stage backing seen in companies like Moderna (MRNA) by Flagship Pioneering or BioNTech (BNTX) by the Strüngmann family, where significant foundational investor stakes provided stability and strategic guidance post-IPO.
• The lock-up agreement is standard practice for IPOs, ensuring orderly market conditions post-listing.

Corporate Governance

Stakeholder Impact

• Shareholders: The significant and continued investment by Longitude Capital and its principals, including a board member, may instill confidence in other shareholders regarding the company's long-term prospects. The lock-up agreement provides short-term stability by preventing immediate sales from these large holders.
• Company (Veradermics): Continued backing from a major venture capital firm provides stability and potentially strategic guidance, especially with a board member involved.

Next Steps

• Reporting Persons will continue to review their investment in Veradermics on an ongoing basis.
• Reporting Persons may acquire or dispose of additional shares of Common Stock or other securities of the Issuer in the future.
• The 180-day lock-up period for Reporting Persons will expire around August 4, 2026.

Key Dates

Recommendation

The filing primarily discloses beneficial ownership and does not contain new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. However, the substantial and continued investment by Longitude Capital, including participation in the IPO by existing preferred shareholders and a board member, suggests a strong vote of confidence in Veradermics' future. The 180-day lock-up period also limits immediate selling pressure from these large holders. Therefore, a 'hold' recommendation is appropriate for existing investors, while potential new investors should await further operational updates before making a decision.

Keywords

Veradermics, Longitude Capital, Schedule 13D, Beneficial Ownership, Common Stock, IPO, Venture Capital, Biotechnology, Pharmaceuticals, Investment, Patrick G. Enright, Juliet Tammenoms Bakker